Smallpox vaccine - Acambis

Drug Profile

Smallpox vaccine - Acambis

Alternative Names: ACAM 3000 MVA; MVA 3000; MVA smallpox vaccine - Acambis

Latest Information Update: 24 Apr 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Acambis
  • Developer Baxter Healthcare Corporation
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Smallpox

Most Recent Events

  • 15 Mar 2007 Discontinued - Phase-I for Smallpox in United Kingdom (Injection)
  • 15 Mar 2007 Discontinued - Phase-II for Smallpox in USA (Injection)
  • 31 Jul 2006 Final results from a phase II clinical trial in Smallpox Prevention have been added to the adverse events and Viral Infection immunogenicity sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top